GENELUX
Genelux Corporation is a privately-held, clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccina virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 ... encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
GENELUX
Industry:
Biopharma Biotechnology Health Diagnostics
Founded:
2001-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.genelux.com
Total Employee:
11+
Status:
Active
Contact:
8584830026
Email Addresses:
[email protected]
Total Funding:
20.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Employees Featured
Founder
Investors List
Woodward Diversified Capital
Woodward Diversified Capital investment in Convertible Note - Genelux
Official Site Inspections
http://www.genelux.com Semrush global rank: 5.66 M Semrush visits lastest month: 1.49 K
- Host name: hwsrv-453764.hostwindsdns.com
- IP address: 23.254.134.180
- Location: Seattle United States
- Latitude: 47.4902
- Longitude: -122.3004
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98168
More informations about "Genelux"
Genelux Corporation | Company
Build our organization into a fully integrated therapeutics company. Facilities. ... Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or …See details»
Genelux Corporation - Wikipedia
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable DNA virus with a large engineering capacity. See details»
Board of Directors - Genelux Corporation
At this time, based on these factors, Genelux believes that participation in one of our clinical trials is the only appropriate way to access our investigational therapies. If the investigational drug is approved by a regulatory agency for …See details»
Genelux - Crunchbase Company Profile & Funding
Organization. Genelux . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Genelux is a biopharmaceutical company that develops diagnostic and therapeutic …See details»
Genelux - LinkedIn
Genelux | 1,200 followers on LinkedIn. Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biotechnology company focused on improving the lives of patients affected by difficult-to …See details»
2022 ANNUAL REPORT - investors.genelux.com
Genelux had an outstanding year in 2022. As always, we want to take a moment to express our gratitude to you, our extraordinary stockholders, for your unwavering support and loyalty. 2022 …See details»
Genelux Corporation (GNLX) Company Profile & Overview - Stock …
Jan 26, 2023 Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in …See details»
Genelux Corp (GNLX-Q) Profile - The Globe and Mail
See the company profile for Genelux Corp (GNLX-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Genelux Corporation | Investors
Oct 22, 2024 Genelux is a Phase 3 biopharmaceutical company developing powerful therapeutics for patients suffering from difficult-to-treat cancers. The Company is focused on …See details»
News Releases - Genelux Corporation
Sep 3, 2024 WESTLAKE VILLAGE, Calif. , May 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today …See details»
Genelux and Newsoara Announce Collaboration and License …
Sep 28, 2021 said Thomas Zindrick, J.D., President and CEO of Genelux. "It is a dynamic organization with a commitment to advancing cutting-edge therapeutics, whose strength in …See details»
Genelux - Funding, Financials, Valuation & Investors - Crunchbase
Genelux is a biopharmaceutical company that develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. Search Crunchbase. ... How much funding has this …See details»
Pipeline - Genelux Corporation
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor …See details»
Redefining Immuno-Oncology - Genelux Corporation
Aug 1, 2021 Except as required by law, Genelux does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future …See details»
Genelux Corporation | Genelux Corporation Initiates a Pivotal …
Sep 21, 2022 Genelux Corporation [email protected]. About The GOG Foundation, Inc. (www.gog.org) The GOG Foundation, Inc. (GOG) is a not-for profit organization with the …See details»
Genelux Corporation (GNLX) Stock Price, Quote & News - Stock …
2 days ago Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from …See details»
Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Jul 11, 2023 Genelux (NASDAQ:GNLX) is an immuno-oncology frontrunner that presents a promising investment opportunity in the fight against cancer.With its cutting-edge technology …See details»
Genelux Corporation Initiates a Pivotal Phase 3 Trial,
Sep 21, 2022 Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from difficult-to …See details»
Technology - Genelux Corporation
Our proprietary Choice TM discovery platform is the foundation of our oncolytic immunotherapy product development program and is designed to allow us to generate new product candidates …See details»